Ayahuasca, a two-plant Amazonian ritual brew containing a short-acting psychedelic, is explored for mood and emotional resilience. Its clearest signals, from few controlled studies, are eased grief and a fast mood lift in depression resistant to standard treatment. Costs are mostly short-lived: vomiting, a brief blood-pressure rise and frightening experiences. Serious harm clusters with psychosis, bipolar disorder, heart or liver disease, or mixing with antidepressants. Longer life is unproven. (Full Review)

Protocol

Clinical research protocol (Natal, Draulio de Araújo group)

1 mL/kg, single supervised dose

Delivers 0.36 mg/kg DMT; about 9:1 vine alkaloids to DMT, taken together

Indigenous and retreat ceremony (Shipibo healers, Peruvian retreat centers)

2–4 night ceremonies over 1–2 weeks

A cup at a time, guided by a healer, combined with a restrictive diet

Single versus split dosing

Second cup often after 1–2 hours

Two doses 4 hours apart raised DMT levels and effects without tolerance

Time to effect

Mood (depression)

By the next day

Mood changes after one dose in the depression trial

Ceremonial benefits

1 to 12 months

Window over which ceremonial studies assessed benefits

Acute effects

Onset 20–60 minutes

Peak at 1.5–2 hours; fade by 4–6 hours

Benefits

Medium: Rapid relief of depressive symptoms; preserved cognitive and executive function in long-term users; reduced grief severity

Low: Reduced anxiety symptoms; reduced suicidal thinking; reduced posttraumatic stress symptoms; reduced alcohol and drug use; better emotion regulation and mindfulness capacities; better wellbeing and quality of life; relief of parkinsonian motor symptoms

Speculative: Neuroplasticity and new nerve cell growth; lower systemic inflammation; regrowth of insulin-producing cells; brain protection after stroke; lifespan extension

Contraindications

Personal history of schizophrenia, schizoaffective disorder, bipolar I disorder or any psychotic episode, or a first-degree relative with these

Pregnancy or breastfeeding

Uncontrolled hypertension (resting blood pressure ≥140/90 mm Hg despite treatment)

Recent heart attack or stroke (<6 months), unstable angina, heart failure (NYHA class III–IV), or QTc >450 ms in men or >470 ms in women

Significant liver disease (Child-Pugh class B or C)

Poorly controlled epilepsy

Pheochromocytoma

Serotonergic drugs or MAOIs when a supervised washout cannot be completed

Active suicidal intent or a suicide attempt within the past 12 months, outside a clinical program

MAOIs (phenelzine, tranylcypromine, selegiline, linezolid, methylene blue)

5-MeO-DMT and MDMA

Key Interactions

SSRIs and SNRIs (sertraline, fluoxetine, escitalopram, venlafaxine, duloxetine)

Tricyclic antidepressants and trazodone (clomipramine, amitriptyline)

Serotonergic opioids and triptans (tramadol, meperidine, methadone, sumatriptan)

Lithium

Stimulants and sympathomimetics (amphetamine, methylphenidate, cocaine, levodopa)

CYP2D6 inhibitors (paroxetine, bupropion, quinidine, terbinafine)

Antipsychotics (quetiapine, olanzapine, risperidone)

Benzodiazepines (lorazepam, alprazolam)

Dextromethorphan and chlorpheniramine

Decongestants (pseudoephedrine, phenylephrine)

Serotonergic supplements (5-HTP, L-tryptophan, SAMe, St. John's wort)

MAO-inhibiting herbs (Syrian rue, passionflower, high-dose Rhodiola rosea)

Stimulant supplements (yohimbe, ephedra, high-dose caffeine)

Other psychedelics (psilocybin, LSD)

Tyramine-rich foods and drinks (aged cheese, cured meats, soy sauce, tap beer)

Kambo frog secretion and tobacco purges (mapacho, rapé)

Cannabis and alcohol

Risk & Side Effects

High: Nausea and vomiting; transient rise in blood pressure and heart rate

Medium: Acute psychological distress and difficult after-effects

Low: Psychotic or manic episodes; serotonin toxicity with serotonergic medications; seizures, fainting and deaths

Speculative: Blood-pressure surge with tyramine-rich foods; harm in pregnancy; harmaline toxicity at high doses; structural brain changes in long-term users; transient immune cell shifts

Monitoring

Marker	Target	Why
Blood pressure	<120/80 mm Hg	Brew raises it acutely
Resting heart rate	50–70 bpm	Brew raises it acutely
QTc interval (ECG)	<440 ms men, <450 ms women	Heart-rhythm safety
ALT and AST	ALT <25 U/L, AST <25 U/L	Liver clears vine alkaloids
Sodium and potassium	Na 138–142 mmol/L; K 4.0–4.8 mmol/L	Purging depletes electrolytes
hs-CRP	<1.0 mg/L	Inflammation reference
PHQ-9	<5	Tracks depressive symptoms
GAD-7	<5	Tracks anxiety symptoms
AUDIT	<8	Tracks alcohol use
C-SSRS	No current suicidal ideation	Suicide-risk screen
Pregnancy test (hCG)	Negative	Excludes fetal exposure
CYP2D6 genotype (optional)	Normal metabolizer	Predicts vine-alkaloid clearance

Cadence: Baseline within 4 weeks before dosing; blood pressure and heart rate before dosing and every 30–60 minutes for the first 4 hours; symptom scales at 1 day, 1 week, 1 month and 3 months after each session; with repeated ceremonial use, full laboratory panel and scales every 6–12 months

Qualitative Assessment

Mood stability and resilience to everyday stress
Emotional reactivity and ease of recovering from upsets
Sleep quality in the week after sessions
Cravings for, and actual use of, alcohol or other drugs
Sense of meaning, connection and relationship quality
Warning signs: intrusive fear, persistent anxiety, or visual disturbances lasting more than 1 week

Ayahuasca for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment